Tag: FDA

October 20, 2016 Off

FDA approves Lilly’s Lartruv for soft tissue sarcoma treatment

By Dino Mustafić

Eli Lilly and Company announced that FDA has granted approval of LARTRUV (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.